3 years ago

Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism

Novel nucleoside analogues targeting HCV replication through an NS5A-dependent inhibition mechanism
Niki Vassilaki, Panagiotis Marakos, Efseveia Frakolaki, Vanesa Madan, Panagiota Karmou, Nicole Pouli, Ralf Bartenschlager, Nikolaos Lougiakis
A series of new tricyclic nucleosides were synthesized and evaluated as hepatitis C virus (HCV) replication inhibitors. Initial screening in a HCV replicon system, derived from a genotype 1b isolate, identified 9-benzylamino-3-(β-D-ribofuranosyl)-3H-imidazo[4′,5′:5,6]pyrido[2,3-b]pyrazine (15d) as the most potent analogue. Comparative assessment of 15d activity against HCV full-length viruses or subgenomic replicons derived from genotypes 1 to 4 revealed a specificity of the compound for genotypes 1 and 3. Surprisingly, resistance mutations selected against 15d were mapped to domains II and III of the non-structural protein 5A (NS5A), but not to the RNA-dependent RNA polymerase residing in NS5B. These results argue that compound 15d might represent a lead for the development of a novel class of NS5A inhibitors. A number of new tricyclic nucleosides were synthesized and their inhibitory potential against HCV was evaluated. The benzylamino derivative 15d reduced HCV replication and possessed selectivity index 4.97 in 1b genotype. Resistance mutation studies were performed, suggesting that this compound could possess a NS5A-dependent mechanism of action, which is unexpected for nucleoside derivatives.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/cbdd.12966

You might also like
Never Miss Important Research

Researcher is an app designed by academics, for academics. Create a personalised feed in two minutes.
Choose from over 15,000 academics journals covering ten research areas then let Researcher deliver you papers tailored to your interests each day.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.